Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

A. Chanan-Khan, M. Egyed, T. Robak, F. A. Martinelli De Oliveira, M. A. Echeveste, S. Dolan, P. Desjardins, J. Z. Blonski, J. Mei, N. Golany, J. Zhang, J. G. Gribben

Research output: Contribution to journalLetter

19 Scopus citations
Original languageEnglish (US)
Pages (from-to)1240-1243
Number of pages4
JournalLeukemia
Volume31
Issue number5
DOIs
StatePublished - May 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Chanan-Khan, A., Egyed, M., Robak, T., Martinelli De Oliveira, F. A., Echeveste, M. A., Dolan, S., Desjardins, P., Blonski, J. Z., Mei, J., Golany, N., Zhang, J., & Gribben, J. G. (2017). Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia, 31(5), 1240-1243. https://doi.org/10.1038/leu.2017.47